TriangleDexamethasone (NCT06533748)
Dexamethasone trial for Acute Lymphoblastic Leukemia (NCT06533748). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged one through eighteen with newly diagnosed B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma meeting high-risk criteria. Some patients qualify after a slow induction response. Enrollment on INITIALL is required.
The idea: inotuzumab delivers a DNA-damaging payload to CD22-bearing cells; blinatumomab connects CD19-bearing cells with T cells. These medicines join multi-stage chemotherapy, including spinal-fluid treatment. Dasatinib is added only for ABL-class fusions. Researchers measure remaining leukemia and safety over roughly two-and-a-quarter years of therapy.
This phase 2 study plans 128 patients. St. Jude sponsors; three US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.